Noninvasive prenatal testing (NIPT), also known as cell-free DNA (cfDNA) screening, is a type of prenatal aneuploidy screening test. With a simple maternal blood draw, NIPT can noninvasively screen for the presence of fetal chromosomal aneuploidies as early as week 10. NIPT is now recommended by the American Society of Obstetricians and Gynecologists (ACOG) and the Society for Maternal-Fetal Medicine (SMFM) for all pregnancies regardless of age or risk.2
NIPT is as safe and simple as a blood draw.2
Gain insights into prenatal genetic health risks with >99% accuracy for trisomies 21, 18, and 13.1
NIPT can be performed as early as week 10 of gestation until term.2
Download this Fast Facts Sheet to get a quick overview of NIPT, and see how early prenatal genetic insights can help your patients and inform your decision-making process.Download
With expanded NIPT, obtain a comprehensive view of all 23 chromosome pairs while limiting risk to your patient. Download this brochure to learn about expanded test options beyond chromosomes 21, 18, and 13.2,3Download
Adopting and implementing NIPT brings several advantages over conventional prenatal serum screening to inform your pregnancy management.4-8
False-positive rate: 0.13%7
unnecessary invasive procedure
False-positive rate: 4%9
unnecessary invasive procedures
Figures shown derived for a hypothetical population of 1000 pregnant women who would receive a false-positive result with each respective test, necessitating confirmatory diagnostic testing.
These pages are intended for healthcare professional audiences. Some solutions referenced in this content may not be available or approved in specific geographies.